FDA OKs Lumateperone (Caplyta), First-in-Class for Schizophrenia
Lumateperone (Caplyta) is a novel antipsychotic that acts synergistically through the serotonergic, dopaminergic, and glutamatergic systems.
Related Articles
Total Neoadjuvant Treatment Bests Surgery in Locally Advanced Rectal Cancer
Researchers investigated the efficacy of total neoadjuvant treatment followed by nonoperative management in patients with locally advanced rectal cancer.
Your Cancer Patient’s Sexual Well-Being Really Matters
But sex health assessments are not yet part of oncological clinical practice, despite studies showing that infertility and sexual dysfunction reduce treatment compliance.
Clinical Advances in MASH: A Guide to Managing Metabolic-Dysfunction Associated Steatohepatitis
The incidence of MASH is on the rise. Learn more about determining risk in your patients and the new and emerging therapies available.
Stop the Clot: Thrombosis Prevention Breakthroughs
Over the past few decades, currently available anticoagulants have proven to be effective at thrombosis prevention, however they are often underutilized, pri…
Implementing NICE Guidance on Lipid Modification for Secondary Prevention of Cardiovascular Disease
Professor Riyaz Patel discusses how cardiologists can implement new NICE targets on lipid lowering for secondary prevention of cardiovascular disease
Infographic: Frustration With Slow Progress on Resident Pay
Medical residents have had 2 straight years with decent pay gains. But because 7 lean years preceded that, they expressed frustration in a Medscape survey.
The Rise of the Machines: A Quickfire Exploration of Artificial Intelligence and Big Data in Oncology
Did you know that artificial intelligence (AI) is shaping the future of oncology? Our expert faculty discuss in this rapid question and answer program!
New Trials in Breast Cancer: Could Your Patient Benefit?
One of your patients might be eligible to enroll in a clinical trial currently recruiting people with breast cancer.
Clinical Advances in MASH: A Guide to Managing Metabolic-Dysfunction Associated Steatohepatitis
The incidence of MASH is on the rise. Learn more about determining risk in your patients and the new and emerging therapies available.
Antihypertenseurs : l’heure de prise n’a pas d’importance dans 2 nouveaux essais
Deux nouveaux essais cliniques BedMed et BedMed-Frail ont confirmé que l’heure de la journée n’a pas d’importance lorsqu’il s’agit de prendre des médicaments antihypertenseurs.